Studying airway microbes and asthma types in adults with asthma
Observes airway microbes and asthma types in adults with asthma.
Plain-language title generated from the registry record
Registry title: Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma
Key facts
- Where
- Shatin, Hong KongSee the site
Where in Hong Kong
- Prince of Wales HospitalShatin, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT04706988
- Record updated
- 19 March 2026
- Original description
Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype and phenotype is not well understood. Knowledge of microbiota in the airway allows exploration of therapeutic manipulation of the microbiome and targeting the development of asthma prevention strategies and the optimization of asthma treatment.Read full original descriptionShow less
Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma
Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype and phenotype is not well understood. Knowledge of microbiota in the airway allows exploration of therapeutic manipulation of the microbiome and targeting the development of asthma prevention strategies and the optimization of asthma treatment.
Inclusion: Subjects aged between 18 and 80 years and have a diagnosis of asthma according to the Global Initiative for Asthma (GINA) document in 2020; Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 200 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable.
Exclusion: Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer; Signs and symptoms of respiratory tract infections (upper or lower) within 4 weeks; Individuals older than 40 years with a smoking history of more than 10 pack-years or significant biomass exposure; Patients currently randomized in other clinical studies; Pregnant women; Current smokers (who have not quit smoking in the past 1 year); Systemic and intranasal antibiotics treatment within 4 weeks.